U.S. markets closed

Genocea Biosciences, Inc. (GNCA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.5300-0.0600 (-2.32%)
At close: 4:00PM EDT

Genocea Biosciences, Inc.

100 Acorn Park Drive
5th Floor
Cambridge, MA 02140
United States
617 876 8191
http://www.genocea.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees72

Key Executives

NameTitlePayExercisedYear Born
Mr. William D. Clark M.B.A.Pres, CEO & Director821.39kN/A1969
Dr. Thomas A. DavisChief Medical Officer631.72kN/A1964
Dr. Girish N. Aakalu Ph.D.Chief Bus. Officer536.42kN/A1975
Ms. Diantha DuvallCFO & Sec.N/AN/A1972
Dr. Jessica Baker FlechtnerChief Scientific OfficerN/AN/A1972
Ms. Jacquelyn L. SumerChief Legal & Compliance OfficerN/AN/AN/A
Dr. Raymond D. Stapleton Jr.Exec. VP of Pharmaceutical Sciences & ManufacturingN/AN/A1971
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy using neoantigen-targeted peripheral cells for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived tumor-specific T cell therapy; and GEN-009, a neoantigen vaccine candidate, delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.

Corporate Governance

Genocea Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.